Dren Bio
Surveying great inventors and businesses
Axial: https://linktr.ee/axialxyz
Axial partners with great founders and inventors. We invest in early-stage life sciences companies such as Appia Bio, Seranova Bio, Delix Therapeutics, Simcha Therapeutics, among others often when they are no more than an idea. We are fanatical about helping the rare inventor who is compelled to build their own enduring business. If you or someone you know has a great idea or company in life sciences, Axial would be excited to get to know you and possibly invest in your vision and company. We are excited to be in business with you — email us at info@axialvc.com
Dren Bio develops antibody therapies for cancer and autoimmunity. Focusing on biologics designed to selectively target and eliminate pathogenic cells and agents. Founded in 2019, their pipeline is made up of two drug discovery programs: DR-01, the lead candidate, which induces antibody-mediated killing of cytotoxic immune cells involved in blood cancers. With potential use in autoimmune diseases too. The lead targets CD94 which is known to be up-regulated on large granular lymphocytic leukemia (LGLL) cells. The MoA is done through depletion of target cells via antibody-dependent cellular cytotoxicity (ADCC) by means of fratricide, a method in which the same cell type induces ADCC on each other. A phase I/II trial has been initiated to assess the safety and efficacy of DR-01 in previously treated LGLL patients.
The second program uses a proprietary bispecific antibody platform to engage myeloid and cancer cells, reprogram the tumor environment, stimulate phagocytosis, and activate T cells for sustained anti-tumor immunity. Partnering with Pfizer in 2022 using technology behind Dren's second drug candidate. Pfizer made an upfront cash payment of $25M to Dren Bio, with the company eligible to potentially receive more than $1B. To advance select oncology programs.
